Last updated: September 8, 2026
SAIZEN is a recombinant human growth hormone, or somatropin, commercialized by Merck KGaA and its U.S. affiliate EMD Serono. Its commercial position has weakened as older growth-hormone products face biosimilar and follow-on competition, while newer once-weekly products target the same adherence problem with fewer injections. Merck does not report SAIZEN revenue as a separate financial line, so the product’s standalone sales trajectory cannot be quantified from public company disclosures. Its strategic value is more closely tied to portfolio continuity, delivery-device know-how, and access to the growth-hormone market than to material group-level revenue contribution.
What is SAIZEN and which patients does it treat?
SAIZEN contains somatropin, a recombinant form of human growth hormone. Depending on jurisdiction, approved uses include pediatric growth hormone deficiency, growth failure associated with certain syndromes, and adult growth hormone deficiency. Product labels and indications vary by country.
SAIZEN is administered by subcutaneous injection. Its commercial platform has included cartridge-based presentations and the easypod electronic injection device, which records dosing information and was designed to support adherence in pediatric patients.
| Product attribute |
SAIZEN |
| Active ingredient |
Somatropin |
| Drug class |
Recombinant human growth hormone |
| Primary use |
Growth hormone deficiency |
| Administration |
Subcutaneous injection |
| Originator |
Serono, later part of Merck KGaA |
| U.S. commercial organization |
EMD Serono |
| Delivery platform |
Cartridge presentations and easypod device in selected markets |
| Reference-product status |
Established biologic with long-expired primary market protection |
| Main competitors |
Genotropin, Humatrope, Norditropin, Omnitrope, Nutropin, Skytrofa, Ngenla |
SAIZEN competes in a specialist market in which treatment decisions depend on endocrinologist preference, reimbursement, injector usability, patient support, product availability, and contracting. Price alone does not determine market share.
How large is the somatropin market?
The global human growth hormone market includes branded somatropin, biosimilars, follow-on biologics, and newer long-acting products. Published market estimates vary materially because some reports include only recombinant growth hormone while others include adjacent endocrine products.
The market has several structural characteristics:
- Pediatric patients account for a major share of treatment volume.
- Growth hormone treatment often continues for several years, creating recurring revenue per patient.
- Payers and governments increasingly scrutinize dose optimization and annual treatment cost.
- Injection frequency is becoming a major competitive factor.
- Long-acting growth hormone products are expanding the market’s competitive definition.
SAIZEN’s legacy daily-injection model places it against both conventional daily products and once-weekly therapies. Merck’s established manufacturing and commercial infrastructure can support continued sales in selected countries, but the product is unlikely to regain a leadership position without a differentiated delivery, pricing, or market-access strategy.
What is the financial trajectory of SAIZEN?
Merck KGaA does not disclose SAIZEN revenue, gross margin, patient numbers, or operating profit as standalone metrics in its annual reports. The product is included within broader Healthcare reporting, which covers multiple therapeutic areas and brands.
This prevents a precise public reconstruction of SAIZEN’s annual sales. The available evidence supports a directional assessment:
| Period |
Financial position |
| Early commercial period |
Growth supported by expansion of recombinant growth hormone use and Serono’s endocrinology franchise |
| Post-2006 |
Product incorporated into Merck KGaA’s Healthcare portfolio after the acquisition of Serono |
| Mature period |
Revenue pressure from established branded competitors, biosimilar entry, and payer controls |
| Current period |
Legacy-product economics, with value concentrated in recurring patients, geographic niches, and device-linked adherence programs |
| Forward outlook |
Flat-to-declining revenue absent new indications, a major device refresh, or improved access terms |
The financial trajectory is shaped by four factors.
Volume erosion
SAIZEN competes with other daily somatropin products that have greater current visibility in some markets. Physicians may remain loyal to established products, but new prescriptions increasingly reflect injector convenience and weekly administration.
Net-price pressure
Growth hormone products are exposed to formulary negotiations, tender systems, specialty-pharmacy controls, and reimbursement restrictions. Public list prices are poor indicators of manufacturer revenue because rebates and discounts can materially reduce net sales.
Product-mix changes
Revenue per patient depends on dose, patient weight, treatment duration, presentation, and delivery system. Adult patients often require individualized dosing, while pediatric dosing changes with body weight and growth response.
Commercial support costs
Patient-support programs, nurse training, electronic adherence tools, and device distribution can protect persistence but increase selling and administrative costs. The economic benefit depends on whether improved persistence offsets those expenses.
When does SAIZEN lose exclusivity?
SAIZEN’s original composition and manufacturing protections are no longer the main commercial barrier. Recombinant somatropin has been marketed for decades, and the relevant core patent term for the original product has expired.
The remaining protection is primarily regulatory, technical, contractual, or market-based:
- Device and injector patents may protect particular delivery systems.
- Manufacturing patents may cover cell lines, purification, formulation, or process controls.
- Trademark rights protect the SAIZEN brand but do not prevent competing somatropin products.
- Country-specific regulatory data protections may have applied during the initial approval period.
- Pediatric exclusivity, where granted, is time-limited and long expired for an older product.
- Market access contracts and physician familiarity may delay switching even after patent expiry.
The product therefore has no meaningful expectation of renewed conventional small-molecule-style exclusivity. Any durable competitive advantage must come from device usability, supply reliability, evidence, reimbursement, or patient-support infrastructure.
What is the FDA and Orange Book status of SAIZEN?
SAIZEN is a biologic rather than a conventional small-molecule drug. Biologic reference products are generally tracked through the FDA’s Purple Book rather than the Orange Book. The Orange Book is primarily used for approved drug products and patent/exclusivity information under the Hatch-Waxman framework.
For SAIZEN, the relevant regulatory questions are:
- Whether the U.S. product remains actively marketed.
- Whether the reference product is listed in the FDA’s biologics database.
- Whether a proposed competitor follows the 351(k) biosimilar pathway.
- Whether any remaining regulatory exclusivity applies.
- Whether the commercial product and injector remain available in the relevant market.
FDA records and manufacturer communications should be checked for current U.S. marketing status because availability can differ by presentation and country. A product may remain approved while experiencing discontinuation, limited distribution, or withdrawal of a specific presentation.
Which companies challenge SAIZEN in the growth-hormone market?
SAIZEN competes with a broad group of originator and follow-on manufacturers.
| Company |
Competing product |
Competitive position |
| Pfizer |
Genotropin |
Established daily somatropin brand with strong endocrinology recognition |
| Eli Lilly |
Humatrope |
Long-established growth hormone product |
| Novo Nordisk |
Norditropin; Sogroya |
Daily and once-weekly growth hormone portfolio |
| Sandoz |
Omnitrope |
Somatropin follow-on product with biosimilar-market relevance |
| Ipsen |
Nutropin in selected markets and historical territories |
Established growth-hormone presence, subject to country-specific availability |
| Ascendis Pharma |
Skytrofa |
Once-weekly lonapegsomatropin |
| Pfizer |
Ngenla |
Once-weekly somatrogon |
| Other regional manufacturers |
Somatropin and biosimilar products |
Price competition, especially in tender and lower-cost markets |
The most important competitive shift is from brand-versus-brand daily somatropin competition to daily-versus-weekly treatment. Once-weekly products can support adherence and reduce injection burden, although acquisition cost, payer coverage, injection-device performance, and long-term clinical experience remain relevant.
What biosimilar and generic entry risks exist for SAIZEN?
Traditional generic substitution does not apply to SAIZEN in the same way it applies to tablets. Somatropin is a biologic, so competitors generally use biosimilar or follow-on regulatory pathways rather than abbreviated generic applications.
The main risks are:
- Price-based substitution through payer or tender systems.
- Biosimilar or follow-on somatropin adoption.
- Formulary exclusion or preferred-product decisions.
- Switching from daily SAIZEN to another daily product.
- Switching from daily SAIZEN to a once-weekly product.
- Loss of device preference when competing injectors offer better usability.
Automatic pharmacy substitution depends on jurisdiction and the specific regulatory designation. Even where a product is interchangeable, physicians and patients may require education and device training before switching.
What formulation and delivery patents protect SAIZEN?
The commercial protection around SAIZEN is more likely to involve product presentation and delivery than the active ingredient itself. Relevant technical areas include:
- Cartridge and injector configuration.
- Dose-setting mechanisms.
- Electronic adherence recording.
- Stability of somatropin in solution.
- Preservative systems.
- Container-closure integrity.
- Protein aggregation control.
- Manufacturing and purification processes.
- Cold-chain handling and packaging.
Device patents can have commercial value even when the underlying drug is mature. Their strength depends on claim scope, remaining patent term, freedom-to-operate analysis, and whether a competitor can design around the protected mechanism.
A device patent usually does not block a competing somatropin product from entering the market. It can restrict use of a particular injector architecture or require a competing manufacturer to use a different delivery system.
Is there Paragraph IV litigation involving SAIZEN?
Paragraph IV litigation is associated with Hatch-Waxman abbreviated new drug applications, which generally apply to small-molecule drugs. SAIZEN’s principal competitive pathway is biologic follow-on or biosimilar regulation, not a conventional Paragraph IV generic filing.
Accordingly, the relevant disputes are more likely to involve:
- Biosimilar patent dance and patent-listing procedures.
- Patent infringement claims under the Biologics Price Competition and Innovation Act.
- Device patent disputes.
- Manufacturing-process patents.
- Trademark and trade-dress claims.
- Contract or supply disputes.
- Regulatory challenges concerning interchangeability or labeling.
No high-value, product-defining SAIZEN Paragraph IV settlement is a central public feature of the product’s current market position. The absence of a prominent Paragraph IV event does not remove competitive risk; it reflects the biologic regulatory framework.
What licensing deals affect SAIZEN?
SAIZEN originated in Serono’s biotechnology and endocrinology portfolio. Merck KGaA acquired Serono in 2006, bringing SAIZEN into the Merck Healthcare business.
The principal strategic transaction is therefore the Serono acquisition rather than a recent SAIZEN-specific licensing agreement. Public Merck financial disclosures do not identify a separate, material SAIZEN licensing stream. Distribution, co-promotion, manufacturing, and local commercialization arrangements may exist by country, but they do not appear to be reported as a distinct global financial category.
How strong is the SAIZEN patent estate?
SAIZEN’s patent estate is commercially mature rather than structurally strong.
| Patent factor |
Assessment |
| Core active ingredient protection |
Weak or expired |
| Original product exclusivity |
Expired |
| Formulation protection |
Potentially relevant by country and presentation |
| Device protection |
Potentially relevant for easypod and related systems |
| Manufacturing protection |
May remain relevant but is difficult to assess from public product-level data |
| Regulatory exclusivity |
Expired for the legacy product in major markets |
| Brand protection |
Continues through trademark rights |
| Overall barrier to entry |
Low to moderate, depending on market and presentation |
The strongest practical barriers are likely to be manufacturing qualification, regulatory comparability, cold-chain capability, physician familiarity, reimbursement access, and device-support infrastructure.
What is the outlook for SAIZEN revenue?
SAIZEN’s likely revenue path is mature and defensive. The product can continue generating cash flow where it has established reimbursement, physician use, and patient-support infrastructure. Growth is less likely without a major repositioning.
Potential revenue-supporting factors include:
- Retention of long-term pediatric patients.
- Strong local distributor relationships.
- Continued availability of the easypod system.
- Supply reliability during competitor shortages.
- Competitive net pricing.
- Use in markets where weekly products are unavailable or poorly reimbursed.
Revenue risks include:
- Conversion to once-weekly products.
- Biosimilar tender losses.
- Reduced pediatric treatment budgets.
- Product discontinuation in selected countries.
- Device obsolescence.
- Manufacturing interruptions.
- Declining physician familiarity among younger specialists.
For valuation purposes, SAIZEN should be treated as a mature biologic brand with limited patent-driven upside. Its contribution is more likely to be incremental within Merck’s Healthcare portfolio than material to consolidated group earnings.
Key Takeaways
- SAIZEN is an established somatropin biologic marketed by Merck KGaA and EMD Serono.
- Merck does not disclose standalone SAIZEN revenue or profitability.
- The product’s original patent and regulatory exclusivity protections have expired.
- Competition comes from daily somatropin brands, biosimilar or follow-on products, and once-weekly growth hormones.
- The relevant regulatory framework is biologic competition, not conventional Paragraph IV generic litigation.
- Device, formulation, manufacturing, reimbursement, and supply-chain factors are more important than core molecule patents.
- SAIZEN’s financial outlook is mature and likely defensive, with declining long-term growth potential absent a commercial or delivery-system reinvention.
- The main commercial risk is patient and payer migration from daily SAIZEN to lower-cost alternatives or once-weekly products.
FAQs
Is SAIZEN a biosimilar?
No. SAIZEN is an originator somatropin product associated with Serono and Merck KGaA. Other somatropin products may use biosimilar or follow-on regulatory pathways.
Is SAIZEN still available in the United States?
Availability depends on the specific presentation and current commercial status. FDA approval, active marketing, and distribution are separate questions, and manufacturer communications should be used to verify current U.S. supply.
What is the difference between SAIZEN and SOGROYA?
SAIZEN is a daily somatropin product. SOGROYA is a once-weekly growth hormone product containing somapacitan-beco, designed to reduce injection frequency.
Does SAIZEN have market exclusivity?
SAIZEN’s original market exclusivity has expired. Any remaining commercial protection is more likely to involve device patents, formulation claims, manufacturing know-how, trademarks, contracts, and reimbursement positioning.
Is SAIZEN material to Merck KGaA revenue?
Merck KGaA does not report SAIZEN as a separate revenue category. Public reporting does not support treating the product as a material standalone driver of consolidated company revenue.
References
-
European Medicines Agency. (n.d.). Saizen: EPAR and product information. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Merck KGaA. (2024). Annual report 2023. https://www.merckgroup.com/en/investors/reports-and-publications/annual-reports.html
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-and-interchangeable-products
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/indext.cfm
-
European Medicines Agency. (n.d.). Growth hormone medicines. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/shortages-safety-concerns/growth-hormone-medicines
